{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T11:36:43Z","timestamp":1761824203987,"version":"3.37.3"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2019,11,13]],"date-time":"2019-11-13T00:00:00Z","timestamp":1573603200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,11,13]],"date-time":"2019-11-13T00:00:00Z","timestamp":1573603200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2020,3]]},"DOI":"10.1007\/s00415-019-09625-1","type":"journal-article","created":{"date-parts":[[2019,11,13]],"date-time":"2019-11-13T16:03:09Z","timestamp":1573660989000},"page":"694-702","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Exit strategies for \u201cneedle fatigue\u201d in multiple sclerosis: a propensity score-matched comparison study"],"prefix":"10.1007","volume":"267","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3237-6267","authenticated-orcid":false,"given":"Luca","family":"Prosperini","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Cortese","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matteo","family":"Lucchini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Boffa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giovanna","family":"Borriello","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Chiara","family":"Buscarinu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fioravante","family":"Capone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diego","family":"Centonze","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chiara","family":"De Fino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniela","family":"De Pascalis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberta","family":"Fantozzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisabetta","family":"Ferraro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Filippi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simonetta","family":"Galgani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudio","family":"Gasperini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shalom","family":"Haggiag","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Doriana","family":"Landi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Girolama","family":"Marfia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giorgia","family":"Mataluni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Enrico","family":"Millefiorini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Massimiliano","family":"Mirabella","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabrizia","family":"Monteleone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Viviana","family":"Nociti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simona","family":"Pontecorvo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silvia","family":"Romano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Serena","family":"Ruggieri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco","family":"Salvetti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carla","family":"Tortorella","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silvana","family":"Zannino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giancarlo","family":"Di Battista","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,11,13]]},"reference":[{"key":"9625_CR1","doi-asserted-by":"publisher","first-page":"1622","DOI":"10.1016\/S0140-6736(18)30481-1","volume":"391","author":"AJ Thompson","year":"2018","unstructured":"Thompson AJ, Baranzini SE, Geurts J, Hemmer B, Ciccarelli O (2018) Multiple sclerosis. Lancet 391:1622\u20131636","journal-title":"Lancet"},{"key":"9625_CR2","volume-title":"Adherence to long-term therapies: evidence for action","author":"E Sabat\u00e9","year":"2003","unstructured":"Sabat\u00e9 E (2003) Adherence to long-term therapies: evidence for action. WHO, Geneva"},{"key":"9625_CR3","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.msard.2015.02.005","volume":"4","author":"P Rieckmann","year":"2015","unstructured":"Rieckmann P, Boyko A, Centonze D et al (2015) Achieving patient engagement in multiple sclerosis: a perspective from the multiple sclerosis in the 21st century steering group. Mult Scler Relat Disord 4:202\u2013218","journal-title":"Mult Scler Relat Disord"},{"key":"9625_CR4","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.jns.2006.05.075","volume":"259","author":"M Clerico","year":"2007","unstructured":"Clerico M, Barbero P, Contessa G, Ferrero C, Durelli L (2007) Adherence to interferon-\u03b2 treatment and results of therapy switching. J Neurol Sci 259:104\u2013108","journal-title":"J Neurol Sci"},{"key":"9625_CR5","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1177\/1352458516657440","volume":"23","author":"KA McKay","year":"2017","unstructured":"McKay KA, Tremlett H, Patten SB, CIHR Team in the Epidemiology and Impact of Comorbidity on Multiple Sclerosis et al (2017) Determinants of non-adherence to disease-modifying therapies in multiple sclerosis: a cross-Canada prospective study. Mult Scler 23:588\u2013596","journal-title":"Mult Scler"},{"issue":"suppl 6","key":"9625_CR6","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1007\/s00415-008-6016-8","volume":"7","author":"T Klauer","year":"2008","unstructured":"Klauer T, Zettl UK (2008) Compliance, adherence, and the treatment of multiple sclerosis. J Neurol 7(suppl 6):87\u201392","journal-title":"J Neurol"},{"key":"9625_CR7","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1007\/s00415-009-0096-y","volume":"256","author":"K Treadaway","year":"2009","unstructured":"Treadaway K, Cutter G, Salter A et al (2009) Factors that influence adherence with disease-modifying therapies in MS. J Neurol 256:568\u2013576","journal-title":"J Neurol"},{"key":"9625_CR8","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1111\/j.1468-1331.2010.03110.x","volume":"18","author":"V Devonshire","year":"2011","unstructured":"Devonshire V, Lapierre Y, Macdonell R, GAP Study Group et al (2011) The Global Adherence Project: a multicenter observational study on adherence to disease-modifying therapies in patients with relapsing-remitting multiple sclerosis. Eur J Neurol 18:69\u201377","journal-title":"Eur J Neurol"},{"key":"9625_CR9","doi-asserted-by":"publisher","first-page":"e35600","DOI":"10.1371\/journal.pone.0035600","volume":"7","author":"O Fernandez","year":"2012","unstructured":"Fernandez O, Aguera E, Izquierdo G, Group on Adherence to IFNB-1\u03b2 in Spain et al (2012) Adherence to interferon-\u03b21b treatment in patients with multiple sclerosis in Spain. PLoS ONE 7:e35600","journal-title":"PLoS ONE"},{"issue":"1 Suppl A","key":"9625_CR10","first-page":"S24","volume":"19","author":"C Nichols","year":"2013","unstructured":"Nichols C, White LA, Friedman M, Pill MW (2013) Narrative review of the literature on adherence to disease-modifying therapies among patients with multiple sclerosis. J Manag Care Pharm 19(1 Suppl A):S24\u2013S40","journal-title":"J Manag Care Pharm"},{"key":"9625_CR11","first-page":"205521731877789","volume":"4","author":"DS Conway","year":"2018","unstructured":"Conway DS, Cecilia Vieira M, Thompson NR et al (2018) Patient-reported disease-modifying therapy adherence in the clinic: a reliable metric? Mult Scler J Exp Transl Clin 4:2055217318777894","journal-title":"Mult Scler J Exp Transl Clin"},{"key":"9625_CR12","doi-asserted-by":"publisher","first-page":"89","DOI":"10.2165\/11533330-000000000-00000","volume":"30","author":"SC Steinberg","year":"2010","unstructured":"Steinberg SC, Faris RJ, Chang CF, Chan A, Tankersley MA (2010) Impact of adherence to interferons in the treatment of multiple sclerosis: a non-experimental, retrospective, cohort study. Clin Drug Investig 30:89\u2013100","journal-title":"Clin Drug Investig"},{"key":"9625_CR13","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1007\/s12325-010-0093-7","volume":"28","author":"H Tan","year":"2011","unstructured":"Tan H, Cai Q, Agarwal S, Stephenson JJ, Kamat S (2011) Impact of adherence to disease-modifying therapies on clinical and economic outcomes among patients with multiple sclerosis. Adv Ther 28:51\u201361","journal-title":"Adv Ther"},{"key":"9625_CR14","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.jns.2004.03.023","volume":"222","author":"P Barbero","year":"2004","unstructured":"Barbero P, Verdun E, Bergui M et al (2004) High-dose, frequently administered interferon-\u03b2 therapy for relapsing-remitting multiple sclerosis must be maintained over the long term: the interferon-\u03b2 dose-reduction study. J Neurol Sci 222:13\u201319","journal-title":"J Neurol Sci"},{"key":"9625_CR15","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1159\/000356786","volume":"71","author":"L Prosperini","year":"2014","unstructured":"Prosperini L, Mancinelli CR, Pozzilli C et al (2014) From high-to low-frequency administered interferon-beta for multiple sclerosis: a multicenter study. Eur Neurol 71:233\u2013241","journal-title":"Eur Neurol"},{"key":"9625_CR16","doi-asserted-by":"publisher","first-page":"e0123824","DOI":"10.1371\/journal.pone.0123824","volume":"10","author":"S Zhornitsky","year":"2015","unstructured":"Zhornitsky S, Greenfield J, Koch MW et al (2015) Long-term persistence with injectable therapy in relapsing-remitting multiple sclerosis: an 18-year observational cohort study. PLoS ONE 10:e0123824","journal-title":"PLoS ONE"},{"key":"9625_CR17","first-page":"1123","volume":"8","author":"M Caporro","year":"2014","unstructured":"Caporro M, Disanto G, Gobbi C, Zecca C (2014) Two decades of subcutaneous glatiramer acetate injection: current role of the standard dose, and new high-dose low-frequency glatiramer acetate in relapsing-remitting multiple sclerosis treatment. Patient Prefer Adherence 8:1123\u20131134","journal-title":"Patient Prefer Adherence"},{"key":"9625_CR18","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.1007\/s00415-018-8831-x","volume":"265","author":"R Lanzillo","year":"2018","unstructured":"Lanzillo R, Prosperini L, Gasperini C, R.I. Re.MS study group et al (2018) A multicentRE observational analysiS of PErsistenCe to Treatment in the new multiple sclerosis era: the RESPECT study. J Neurol 265:1174\u20131183","journal-title":"J Neurol"},{"key":"9625_CR19","doi-asserted-by":"publisher","DOI":"10.1177\/1352458518790390","author":"F Sacc\u00e0","year":"2018","unstructured":"Sacc\u00e0 F, Lanzillo R, Signori A, iMUST Group et al (2018) Determinants of therapy switch in multiple sclerosis treatment-na\u00efve patients: a real-life study. Mult Scler. https:\/\/doi.org\/10.1177\/1352458518790390","journal-title":"Mult Scler"},{"key":"9625_CR20","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1016\/j.msard.2018.11.004","volume":"27","author":"S Setayeshgar","year":"2019","unstructured":"Setayeshgar S, Kingwell E, Zhu F et al (2019) Persistence and adherence to the new oral disease-modifying therapies for multiple sclerosis: a population-based study. Mult Scler Relat Disord 27:364\u2013369","journal-title":"Mult Scler Relat Disord"},{"key":"9625_CR21","unstructured":"Percorso Diagnostico Terapeutico Assistenziale (PDTA) Regione Lazio. regione.lazio.it\/binary\/rl_sanita\/tbl_normativa\/SAN_DCA_U00386_13_11_2014.pdf. Accessed 28 Sep 2018"},{"key":"9625_CR22","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/S1474-4422(17)30470-2","volume":"17","author":"AJ Thompson","year":"2018","unstructured":"Thompson AJ, Banwell BL, Barkhof F et al (2018) Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol 17:162\u2013173","journal-title":"Lancet Neurol"},{"issue":"33","key":"9625_CR23","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1212\/WNL.33.11.1444","volume":"1983","author":"JF Kurtzke","year":"1983","unstructured":"Kurtzke JF (1983) Rating neurologic impairment in multiple sclerosis: an Expanded Disability Status Scale (EDSS). Neurology 1983(33):1444\u20131452","journal-title":"Neurology"},{"key":"9625_CR24","first-page":"90","volume":"16","author":"M Trojano","year":"2009","unstructured":"Trojano M, Pellegrini F, Paolicelli D, Fuiani A, Di Renzo V (2009) Observational studies: propensity score analysis of non-randomized data. Int MS J 16:90\u201397","journal-title":"Int MS J"},{"key":"9625_CR25","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1002\/pds.2121","volume":"20","author":"JA Rassen","year":"2011","unstructured":"Rassen JA, Solomon DH, Glynn RJ, Schneeweiss S (2011) Simultaneously assessing intended and unintended treatment effects of multiple treatment options: a pragmatic \u2018\u2018matrix design\u2019\u2019. Pharmacoepidemiol Drug Saf 20:675\u2013683","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"9625_CR26","doi-asserted-by":"publisher","first-page":"3083","DOI":"10.1002\/sim.3697","volume":"28","author":"PC Austin","year":"2009","unstructured":"Austin PC (2009) Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples. Stat Med 28:3083\u20133107","journal-title":"Stat Med"},{"key":"9625_CR27","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1093\/epirev\/mxg002","volume":"25","author":"P Cummings","year":"2003","unstructured":"Cummings P, McKnight B, Greenland S (2003) Matched cohort methods for injury research. Epidemiol Rev 25:43\u201350","journal-title":"Epidemiol Rev"},{"key":"9625_CR28","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1093\/ije\/25.6.1107","volume":"25","author":"S Greenland","year":"1996","unstructured":"Greenland S (1996) Basic methods for sensitivity analysis of biases. Int J Epidemiol 25:1107\u20131116","journal-title":"Int J Epidemiol"},{"key":"9625_CR29","first-page":"101","volume":"5","author":"N Girouard","year":"2011","unstructured":"Girouard N, Soucy N (2011) Patient considerations in the management of multiple sclerosis: development and clinical utility of oral agents. Patient Prefer Adherence 5:101\u2013108","journal-title":"Patient Prefer Adherence"},{"key":"9625_CR30","doi-asserted-by":"publisher","first-page":"261","DOI":"10.2147\/PPA.S187983","volume":"13","author":"RM Verdugo","year":"2019","unstructured":"Verdugo RM, Herr\u00e1iz ER, Fern\u00e1ndez-Del Olmo R, Bonet MR, Garc\u00eda MV (2019) Adherence to disease-modifying treatments in patients with multiple sclerosis in Spain. Patient Prefer Adherence 13:261\u2013272","journal-title":"Patient Prefer Adherence"},{"key":"9625_CR31","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.msard.2018.08.012","volume":"26","author":"BA Hendin","year":"2018","unstructured":"Hendin BA (2018) Peg-interferon beta-1a for the treatment of relapsing multiple sclerosis: a case series. Mult Scler Relat Disord 26:33\u201336","journal-title":"Mult Scler Relat Disord"},{"key":"9625_CR32","doi-asserted-by":"publisher","first-page":"e0210417","DOI":"10.1371\/journal.pone.0210417","volume":"14","author":"P Duquette","year":"2019","unstructured":"Duquette P, Yeung M, Mouallif S et al (2019) A retrospective claims analysis: compliance and discontinuation rates among Canadian patients with multiple sclerosis treated with disease-modifying therapies. PLoS ONE 14:e0210417","journal-title":"PLoS ONE"},{"issue":"11","key":"9625_CR33","doi-asserted-by":"crossref","first-page":"175628641879640","DOI":"10.1177\/1756286418796404","volume":"10","author":"E D\u2019Amico","year":"2018","unstructured":"D\u2019Amico E, Zangh\u00ec A, Callari G et al (2018) Comparable efficacy and safety of dimethyl fumarate and teriflunomide treatment in Relapsing-Remitting Multiple Sclerosis: an Italian real-word multicenter experience. Ther Adv Neurol Disord. 10(11):1756286418796404","journal-title":"Ther Adv Neurol Disord."},{"key":"9625_CR34","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1007\/s00415-018-9144-9","volume":"266","author":"E D\u2019Amico","year":"2019","unstructured":"D\u2019Amico E, Zangh\u00ec A, Sciandra M et al (2019) Discontinuation of teriflunomide and dimethyl fumarate in a large Italian multicentre population: a 24-month real-world experience. J Neurol 266:411\u2013416","journal-title":"J Neurol"},{"key":"9625_CR35","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1136\/jnnp-2018-319831","volume":"90","author":"T Kalincik","year":"2019","unstructured":"Kalincik T, Havrdova E, Horakova D et al (2019) Comparison of fingolimod, dimethyl fumarate and teriflunomide for multiple sclerosis. J Neurol Neurosurg Psychiatry 90:458\u2013468","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"9625_CR36","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000007938","author":"DA Laplaud","year":"2019","unstructured":"Laplaud DA, Casey R, Barbin L, SFSEP and OFSEP groups et al (2019) Comparative effectiveness of teriflunomide vs dimethyl fumarate in multiple sclerosis. Neurology. https:\/\/doi.org\/10.1212\/WNL.0000000000007938","journal-title":"Neurology"},{"key":"9625_CR37","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1177\/1352458516633902","volume":"23","author":"T Kalincik","year":"2017","unstructured":"Kalincik T, Sormani MP (2017) Reporting treatment outcomes in observational data: a fine balance. Mult Scler 23:21\u201322","journal-title":"Mult Scler"},{"key":"9625_CR38","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1080\/00031305.1985.10479383","volume":"39","author":"PR Rosenbaum","year":"1985","unstructured":"Rosenbaum PR, Rubin DB (1985) Constructing a control group using multivariate matched sampling methods that incorporate the propensity score. Am Stat 39:33\u201338","journal-title":"Am Stat"},{"key":"9625_CR39","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1002\/sim.2580","volume":"26","author":"PC Austin","year":"2007","unstructured":"Austin PC, Grootendorst P, Anderson GM (2007) A comparison of the ability of different propensity score models to balance measured variables between treated and untreated subjects: a Monte Carlo study. Stat Med 26:734\u2013753","journal-title":"Stat Med"},{"key":"9625_CR40","doi-asserted-by":"publisher","first-page":"e000953","DOI":"10.1136\/rmdopen-2019-000953","volume":"5","author":"SA Bergstra","year":"2019","unstructured":"Bergstra SA, Sepriano A, Ramiro S, Landew\u00e9 R (2019) Three handy tips and a practical guide to improve your propensity score models. RMD Open 5:e000953","journal-title":"RMD Open"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-019-09625-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00415-019-09625-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-019-09625-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,26]],"date-time":"2024-07-26T21:31:39Z","timestamp":1722029499000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00415-019-09625-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,13]]},"references-count":40,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,3]]}},"alternative-id":["9625"],"URL":"https:\/\/doi.org\/10.1007\/s00415-019-09625-1","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"type":"print","value":"0340-5354"},{"type":"electronic","value":"1432-1459"}],"subject":[],"published":{"date-parts":[[2019,11,13]]},"assertion":[{"value":"4 September 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 November 2019","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 November 2019","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 November 2019","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standard"}},{"value":"On behalf of all authors, the corresponding author states that there is no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"The present study was performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments. The local ethical committee boards provided exemption of approval for non-interventional studies. We obtained an informed consent from each participant prior to any study procedure. In no way, this study did interfere in the care received by patients.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical statement"}}]}}